Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2017-03-23 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
第八届董事会第六十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 69th meeting of the 8th Board of Directors of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details decisions on acquisition approval and organizational restructuring, including voting results and attendance. It also includes a brief biography of a board secretary assistant. There is no financial data, earnings information, or report publication mentioned. The content focuses on board decisions and management changes, which aligns with Board/Management Information filings. The document length is short and it is not a report or announcement of a report publication, so it is not an Annual Report or Regulatory Filing. Therefore, the best classification is Board/Management Information (MANG).
2017-03-23 Chinese
独立董事关于关联交易事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on a related party transaction, referencing regulatory guidelines from the China Securities Regulatory Commission and stock exchange listing rules. It discusses the fairness and independence of the transaction evaluation and confirms compliance with legal and procedural requirements. The content is a formal opinion related to governance and transaction approval, not a full financial report, earnings release, or announcement of voting results. It does not contain financial statements or detailed financial data. This type of document fits best under Regulatory Filings (RNS), as it is a compliance-related disclosure that does not fit other specific categories.
2017-03-23 Chinese
关于收购深圳盈泰泓康创业投资合伙企业（有限合伙）28%合伙份额暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of a 28% partnership interest in an investment partnership (Shenzhen Yingtai Hongkang Venture Capital Partnership) by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes extensive information about the transaction, parties involved, financial data, asset valuation, agreements, and the board's approval process. The content focuses on a specific capital transaction involving related parties and investment fund interests. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a call transcript, nor a governance or remuneration report. The document is a formal announcement of a capital acquisition and related party transaction, which fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is the announcement itself, not a brief notice or report publication announcement.
2017-03-23 Chinese
高级管理人员辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management member, specifically the Vice General Manager and Board Secretary. It details the resignation date, the temporary replacement, and expresses gratitude for the individual's contributions. There is no financial data, no mention of a report or meeting, and no regulatory or legal proceedings discussed. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2017-03-17 Chinese
2017年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2017 second extraordinary shareholders' meeting of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details the meeting date, attendance, voting results on a major asset restructuring suspension proposal, and legal witness statements. The content focuses on the official announcement of shareholder meeting decisions and voting outcomes rather than the meeting materials or presentations themselves. The document length is short (1635 characters), and it is a formal announcement of the meeting resolutions and voting results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2017-03-10 Chinese
2017年第二次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and legality of a company's 2017 second extraordinary shareholders' meeting. It details the meeting's notice, attendance, voting procedures, and results. It does not contain financial statements or performance data, nor is it a report or announcement of financial results. It is a legal proceeding related document concerning shareholder meeting legality and compliance. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2017-03-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.